Global Penny Stocks To Watch In March 2025

Global markets have recently faced challenges, with U.S. stocks experiencing significant declines amid trade policy uncertainty and inflation concerns. Despite these headwinds, investors continue to explore opportunities in various sectors, including the often-overlooked realm of penny stocks. While the term 'penny stock' may seem outdated, it still represents a valuable investment area where smaller or newer companies can offer growth potential when supported by strong financials and fundamentals.

Top 10 Penny Stocks Globally

Name	Share Price	Market Cap	Financial Health Rating
NEXG Berhad (KLSE:DSONIC)	MYR0.27	MYR751.18M	★★★★★★
Warpaint London (AIM:W7L)	£3.65	£294.87M	★★★★★★
DXN Holdings Bhd (KLSE:DXN)	MYR0.505	MYR2.51B	★★★★★★
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD2.39	SGD9.44B	★★★★★☆
EZZ Life Science Holdings (ASX:EZZ)	A$1.69	A$81.61M	★★★★★★
Sarawak Plantation Berhad (KLSE:SWKPLNT)	MYR2.28	MYR636.19M	★★★★★★
Angler Gaming (NGM:ANGL)	SEK3.79	SEK284.19M	★★★★★★
Next 15 Group (AIM:NFG)	£2.92	£290.41M	★★★★☆☆
Cloudpoint Technology Berhad (KLSE:CLOUDPT)	MYR0.77	MYR409.33M	★★★★★★
Lever Style (SEHK:1346)	HK$1.28	HK$844.27M	★★★★★★

Click here to see the full list of 5,709 stocks from our Global Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Liuzhou Chemical Industry (SHSE:600423)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Liuzhou Chemical Industry Co., Ltd. is a company engaged in the production and sale of hydrogen peroxide in China, with a market capitalization of approximately CN¥2.51 billion.

Operations: The company's revenue segment is primarily derived from the Chemical Industry, generating CN¥178.44 million.

Market Cap: CN¥2.51B

Liuzhou Chemical Industry's market capitalization stands at approximately CN¥2.51 billion, with a revenue segment primarily from the chemical industry generating CN¥178.44 million. The company has no debt, and its short-term assets of CN¥484.1 million significantly exceed its liabilities, indicating strong liquidity. Despite a volatile share price recently, earnings growth has been robust at 381.3% over the past year, surpassing both its historical average and industry benchmarks. Its Price-To-Earnings ratio of 26.9x suggests it may be undervalued compared to the broader Chinese market average of 38.5x, although Return on Equity remains relatively low at 16.9%.

• Click here to discover the nuances of Liuzhou Chemical Industry with our detailed analytical financial health report.
• Gain insights into Liuzhou Chemical Industry's past trends and performance with our report on the company's historical track record.

Wenfeng Great World Chain Development (SHSE:601010)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Wenfeng Great World Chain Development Corporation operates a commercial retail chain in China, with a market cap of CN¥5.58 billion.

Operations: The company's revenue primarily comes from its operations in China, totaling CN¥1.93 billion.

Market Cap: CN¥5.58B

Wenfeng Great World Chain Development's market cap is CN¥5.58 billion, with revenue of CN¥1.93 billion from its Chinese retail operations. The company faces challenges with a low Return on Equity of 2.6% and declining earnings, down 25.6% annually over five years. Short-term liabilities exceed short-term assets (CN¥1.8B vs CN¥1.3B), raising liquidity concerns despite having more cash than debt and sufficient interest coverage by profits. A dividend yield of 2.39% is not well supported by earnings or free cash flow, while the management team and board are relatively inexperienced with average tenures under three years each.

• Navigate through the intricacies of Wenfeng Great World Chain Development with our comprehensive balance sheet health report here.
• Assess Wenfeng Great World Chain Development's previous results with our detailed historical performance reports.

HARBIN GLORIA PHARMACEUTICALS (SZSE:002437)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Harbin Gloria Pharmaceuticals Co., Ltd focuses on the research, development, production, and sale of pharmaceutical products mainly in China with a market cap of CN¥5.52 billion.

Operations: Harbin Gloria Pharmaceuticals Co., Ltd has not reported any specific revenue segments.

Market Cap: CN¥5.52B

Harbin Gloria Pharmaceuticals, with a market cap of CN¥5.52 billion, has recently become profitable, yet its Return on Equity remains low at 4.7%. The company's short-term liabilities slightly exceed its short-term assets (CN¥871.9M vs CN¥870.4M), indicating tight liquidity management despite having more cash than total debt and reducing its debt-to-equity ratio significantly over five years. Recent board changes reflect investor activism with new director appointments aiming to strengthen governance. Although earnings have grown significantly over the past five years, the presence of large one-off gains impacts financial clarity and stability assessments for potential investors in this volatile space.

• Click to explore a detailed breakdown of our findings in HARBIN GLORIA PHARMACEUTICALS' financial health report.
• Gain insights into HARBIN GLORIA PHARMACEUTICALS' outlook and expected performance with our report on the company's earnings estimates.

Next Steps

• Investigate our full lineup of 5,709 Global Penny Stocks right here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com